{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:39:21Z","timestamp":1792471161132,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Obstructive sleep apnea affects approximately one billion adults worldwide and is associated with hypertension, atrial fibrillation, heart failure, and stroke. Obesity is its dominant reversible cause, yet positive airway pressure therapy splints the pharyngeal airway without addressing the adiposity that narrows it, and randomized trials have not shown that it reduces cardiovascular events. In December 2024, the United States Food and Drug Administration approved tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as the first drug for moderate-to-severe obstructive sleep apnea in adults with obesity. We summarize the pharmacology of tirzepatide and the anatomic basis by which weight reduction improves upper airway patency, notably reduction of tongue and parapharyngeal fat. We then review the SURMOUNT-OSA program: two parallel 52-week, double-blind, placebo-controlled phase 3 trials enrolling 469 adults with obesity and an apnea-hypopnea index of at least 15 events per hour, one conducted without positive airway pressure and one during established positive airway pressure use. Tirzepatide reduced the apnea-hypopnea index by an estimated 20.0 and 23.8 events per hour relative to placebo, with concurrent reductions in sleep apnea-specific hypoxic burden, body weight, systolic blood pressure, and high-sensitivity C-reactive protein.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000001504","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:01:57Z","timestamp":1792468917000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tirzepatide for Obstructive Sleep Apnea: Trial Evidence, Cardiometabolic Effects, and Implications for Cardiovascular Practice"],"prefix":"10.1097","author":[{"given":"Fatima Safi","family":"Arslan","sequence":"first","affiliation":[{"name":"From the Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimsha","family":"Ahmad","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"R1-20261020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-2600(19)30198-5","article-title":"Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.","volume":"7","author":"Benjafield","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R2-20261020","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.2020.3514","article-title":"Diagnosis and management of obstructive sleep apnea: a review.","volume":"323","author":"Gottlieb","year":"2020","journal-title":"JAMA"},{"key":"R3-20261020","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.284.23.3015","article-title":"Longitudinal study of moderate weight change and sleep-disordered breathing.","volume":"284","author":"Peppard","year":"2000","journal-title":"JAMA"},{"key":"R4-20261020","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201807-1326ST","article-title":"The role of weight management in the treatment of adult obstructive sleep apnea. An official American Thoracic Society clinical practice guideline.","volume":"198","author":"Hudgel","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R5-20261020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for prevention of cardiovascular events in obstructive sleep apnea.","volume":"375","author":"McEvoy","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20261020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/thoraxjnl-2014-205361","article-title":"Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials.","volume":"70","author":"Drager","year":"2015","journal-title":"Thorax"},{"key":"R7-20261020","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMe2407117","article-title":"Entering a new era in sleep-apnea treatment.","volume":"391","author":"Patel","year":"2024","journal-title":"N Engl J Med"},{"key":"R8-20261020","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20261020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R10-20261020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.sleep.2025.02.010","article-title":"Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials.","volume":"129","author":"Kow","year":"2025","journal-title":"Sleep Med"},{"key":"R11-20261020","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1164\/rccm.201903-0692OC","article-title":"Effect of weight loss on upper airway anatomy and the apnea-hypopnea index. The importance of tongue fat.","volume":"201","author":"Wang","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-20261020","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s11325-022-02734-8","article-title":"The effect of surgical weight loss on upper airway fat in obstructive sleep apnoea.","volume":"27","author":"Sutherland","year":"2023","journal-title":"Sleep Breath"},{"key":"R13-20261020","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"R14-20261020","doi-asserted-by":"crossref","first-page":"107516","DOI":"10.1016\/j.cct.2024.107516","article-title":"Tirzepatide for the treatment of obstructive sleep apnea: rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial.","volume":"141","author":"Malhotra","year":"2024","journal-title":"Contemp Clin Trials"},{"key":"R15-20261020","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity.","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"R17-20261020","doi-asserted-by":"crossref","first-page":"106719","DOI":"10.1016\/j.sleep.2025.106719","article-title":"Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.","volume":"134","author":"Kanu","year":"2025","journal-title":"Sleep Med"},{"key":"R18-20261020","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1093\/eurheartj\/ehz274","article-title":"Hypoxic burden captures sleep apnoea-specific nocturnal hypoxaemia.","volume":"40","author":"Azarbarzin","year":"2019","journal-title":"Eur Heart J"},{"key":"R20-20261020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41591-025-04071-1","article-title":"Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.","volume":"32","author":"Malhotra","year":"2026","journal-title":"Nat Med"},{"key":"R21-20261020","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsag116","article-title":"Perspective\u2014weight loss, obstructive sleep apnea therapy, or both for cardiometabolic risk in obesity-related obstructive sleep apnea?","volume":"49","author":"Nokes","year":"2026","journal-title":"Sleep"},{"key":"R22-20261020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13679-024-00592-x","article-title":"Estimating cardiovascular benefits of tirzepatide in sleep apnea and obesity: insight from the SURMOUNT-OSA trials.","volume":"13","author":"Beccuti","year":"2024","journal-title":"Curr Obes Rep"},{"key":"R24-20261020","first-page":"656","article-title":"FDA approves tirzepatide as first drug for obstructive sleep apnea.","volume":"333","author":"Anderer","year":"2025","journal-title":"JAMA"},{"key":"R26-20261020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity.","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"R27-20261020","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes.","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"R28-20261020","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamacardio.2026.0767","article-title":"Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the SURPASS-CVOT randomized clinical trial.","volume":"11","author":"Nissen","year":"2026","journal-title":"JAMA Cardiol"},{"key":"R29-20261020","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaf004","article-title":"A meta-analysis of glucagon-like peptide 1 receptor and dual agonists for the treatment of obstructive sleep apnea: end of the story or just the beginning?","volume":"48","author":"Drager","year":"2025","journal-title":"Sleep"},{"key":"R30-20261020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy.","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000001504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:02:01Z","timestamp":1792468921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000001504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001504","relation":{},"ISSN":["1538-4683","1061-5377"],"issn-type":[{"value":"1538-4683","type":"electronic"},{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}